Amended Statement of Beneficial Ownership (sc 13d/a)

SCHEDULE 13D

Under the Securities Exchange Act of 1934
AMENDMENT NO. 1

Novelion Therapeutics Inc.
(Name of Issuer)

Common Shares
(Title of Class of Securities)

67001K202
(CUSIP Number)

Sayuri Childs, Chief Compliance Officer
c/o EdgePoint Investment Group Inc.
150 Bloor Street West, Suite 500
Toronto, Ontario M5S 2X9 Canada
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 26, 2018
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP NO. 67001K202

1	NAMES OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	EdgePoint Investment Group Inc.

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☒

3	SEC USE ONLY


4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	OO

5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐


6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Ontario, Canada

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0

		8	SHARED VOTING POWER
			2,456,062*

		9	SOLE DISPOSITIVE POWER
			0

		10	SHARED DISPOSITIVE POWER
			2,456,062*

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	2,456,062*

12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐


13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	* 12.95% (based on 18,704,857 outstanding shares of the Issuer as of May 7, 2018, plus 261,001 in underlying convertible securities which were beneficially owned by the reporting person and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended (the "Act")

14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IV

SCHEDULE 13D

CUSIP NO. 67001K202

1	NAMES OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	EdgePoint Canadian Portfolio

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☒

3	SEC USE ONLY


4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	OO

5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐


6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Ontario, Canada

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0

		8	SHARED VOTING POWER
			1,370,249*

		9	SOLE DISPOSITIVE POWER
			0

		10	SHARED DISPOSITIVE POWER
			1,370,249*

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,370,249*

12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐


13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	* 7.32% (based on 18,704,857 outstanding shares of the Issuer as of May 7, 2018, plus 19,926 in underlying convertible securities which are beneficially owned by the reporting person and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended (the "Act").

14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IV

SCHEDULE 13D

CUSIP NO. 67001K202

1	NAMES OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	EdgePoint Canadian Growth and Income Portfolio

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☒

3	SEC USE ONLY


4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	OO

5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐


6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Ontario, Canada

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0

		8	SHARED VOTING POWER
			906,887

		9	SOLE DISPOSITIVE POWER
			0

		10	SHARED DISPOSITIVE POWER
			906,887

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	906,887

12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐


13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	4.83% (based on 18,704,857 outstanding shares of the Issuer as of May 7, 2018, plus 62,147 in underlying convertible securities which are beneficially owned by the reporting person and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended (the "Act").

14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IV

SCHEDULE 13D

CUSIP NO. 67001K202

1	NAMES OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	EdgePoint Global Growth and Income Portfolio

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☒

3	SEC USE ONLY


4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	OO

5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐


6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Ontario, Canada

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0

		8	SHARED VOTING POWER
			178,926*

		9	SOLE DISPOSITIVE POWER
			0

		10	SHARED DISPOSITIVE POWER
			178,926*

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	178,926*

12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐


13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	* <1% based on 18,704,857 outstanding shares of the Issuer as of May 7, 2018, plus 178,926 in underlying convertible securities which are beneficially owned by the reporting person and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended (the "Act").

14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IV

SCHEDULE 13D

CUSIP NO. 67001K202

Item 1. Security and Issuer.
- ------ -------------------

Novelion Therapeutics Inc.
c/o Norton Rose Fulbright
1800 – 510 West Georgia Street
Vancouver, British Columbia V6B 0M3 Canada

Common shares, no par value

Item 2. Identity and Background.
- ------ -----------------------

(a)

(i) EdgePoint Investment Group, Inc. ("EdgePoint")
(ii) EdgePoint Canada Portfolio ("ECP")

(iii) EdgePoint Canadian Growth and Income Portfolio ("ECGIP")

(iv) EdgePoint Global Growth and Income Portfolio ("EGGIP")

(v) The executive officers and directors of EdgePoint as of June 26, 2018 are set forth on Schedule I attached hereto, with contains the following information with respect to each such person: name; business address; present business occupation or employment and the name and address of any corporation or other organization in which such employment is conducted; and citizenship.

(b)	Business address: 150 Bloor Street West, Suite 500, Toronto, Ontario M5S 2X9 Canada

(c)	Present occupation: Investment company

(d)	Criminal proceedings and convictions: There were no criminal proceedings during the last five years referred to in Item 2(d), in which EdgePoint, ECP, EGCIP or EGGIP, or the executive officers and directors listed on Schedule I, were convicted.

(e)

Civil proceedings and judgment, decree or order: There were no civil proceedings during the last five years referred to in Item 2(e), in which EdgePoint, ECP, EGCIP or EGGIP, or the executive officers and directors listed on Schedule I, were a party and were or are subject to a judgment, decree or final order.

(f)	Citizenship: Ontario, Canada

Item 3. Source and Amount of Funds or Other Consideration.
- ------ ------------------------------------------------

Working capital of EdgePoint

SCHEDULE 13D

CUSIP NO. 67001K202

Item 4. Purpose of Transaction.
- ------ ----------------------

EdgePoint and ECP filed a Schedule 13G on December 8, 2017, reporting joint ownership of greater than 5% of the outstanding securities of the Issuer. The Schedule 13G was subsequently amended on February 13, 2018. All purchases were made for investment purposes. On June 26, 2018, EdgePoint and ECP, determined that they no longer held the securities with neither the purpose nor effect of changing or influencing control of the Issuer and notified the Issuer of such change of intent in writing.

Item 5. Interest in Securities of the Issuer.
- ------ ------------------------------------

EdgePoint: 2,456,062 common shares, including 261,001 common shares underlying convertible notes in Aegerion Pharmaceuticals, Inc., a subsidiary of the Issuer ("Aegerion").

ECP: 1,370,249 common shares, including 19,926 common shares underlying Aegerion convertible notes

ECGIP: 906,887 common shares, including 62,147 common shares underlying Aegerion convertible notes

EGGIP: 178,926 common shares underlying Aegerion convertible notes

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
- ------ ------------------------------------

None

Item 7. Materials to be Filed as Exhibits.
- ------ ------------------------------------

None

SCHEDULE 13D

CUSIP NO. 67001K202

Signed: July 16, 2018

EDGEPOINT INVESTMENT GROUP INC.

By: /s/ Sayuri Childs
Sayuri Childs, Chief Compliance Officer

EDGEPOINT CANADIAN PORTFOLIO
By: EdgePoint Investment Group Inc.

By: /s/ Sayuri Childs
Sayuri Childs, Chief Compliance Officer

EDGEPOINT CANADIAN GROWTH AND INCOME PORTFOLIO
By: EdgePoint Investment Group Inc.

By: /s/ Sayuri Childs
Sayuri Childs, Chief Compliance Officer

EDGEPOINT GLOBAL GROWTH AND INCOME PORTFOLIO
By: EdgePoint Investment Group Inc.

By: /s/ Sayuri Childs
Sayuri Childs, Chief Compliance Officer

JOINT FILING AGREEMENT

PURSUANT TO SECTION 240.13D-1 (K)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that it knows or has reason to believe that such information is inaccurate.

EDGEPOINT INVESTMENT GROUP INC.


By:		/s/ Sayuri Childs
		Sayuri Childs, Chief Compliance Officer

EDGEPOINT CANADIAN PORTFOLIO

By: EdgePoint Investment Group Inc.


By:		/s/ Sayuri Childs
		Sayuri Childs, Chief Compliance Officer

EDGEPOINT CANADIAN GROWTH AND INCOME PORTFOLIO

By: EdgePoint Investment Group Inc.


By:		/s/ Sayuri Childs
		Sayuri Childs, Chief Compliance Officer

EDGEPOINT GLOBAL GROWTH AND INCOME PORTFOLIO

By: EdgePoint Investment Group Inc.


By:		/s/ Sayuri Childs
		Sayuri Childs, Chief Compliance Officer

SCHEDULE I

Name	Office(s) held	Citizenship
Patrick Farmer	Chair of the Board and Chief Operating Officer of EdgePoint	Canadian
Geoffrey MacDonald	Chief Investment Officer and Co-Chief Executive Officer of EdgePoint	Canadian
Tye Bousada	President and Co-Chief Executive Officer of EdgePoint	Canadian
Norman Tang	Director of Finance of EdgePoint	Canadian
Diane Rossi	Director of Operations of EdgePoint	Canadian
Sayuri Childs	Chief Compliance Officer of EdgePoint	Canadian